Harvard Bioscience, Inc. (HBIO)

Harvard Bioscience Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	86.55	94.14	112.25	113.34	118.9
Revenue Growth (YoY)	-8.06%	-16.14%	-0.96%	-4.68%	16.46%
Cost of Revenue	36.64	39.37	46.18	52.52	51.25
Gross Profit	49.91	54.77	66.07	60.82	67.65
Selling, General & Admin	36.96	43.71	46.82	49.53	48.95
Depreciation & Amortization Expenses	4.03	5.26	5.53	6.12	5.84
Research & Development	8.83	10.41	11.76	12.33	10.8
Other Operating Expenses	48.68	1.61	0.07	-0.23	-
Total Operating Expenses	98.49	60.98	64.18	67.75	65.59
Operating Income	-48.58	-6.21	1.89	-6.93	2.07
Interest Expense	-4.92	-3.54	-3.59	-2.55	-1.54
Other Non-Operating Income (Expense)	-12.7	-7.37	-5.31	-1.94	-2.87
Total Non-Operating Income (Expense)	-17.61	-10.91	-8.9	-4.49	-4.41
Pretax Income	-66.19	-17.12	-7.01	-11.43	-2.35
Provision for Income Taxes	-0.69	0.74	0.86	0.34	0.15
Net Income	-56.7	-12.41	-3.42	-9.52	-0.29
Net Income to Common	-56.7	-12.41	-3.42	-9.52	-0.29
Shares Outstanding (Basic)	4	4	4	4	4
Shares Outstanding (Diluted)	4	4	4	4	4
Shares Change (YoY)	1.96%	2.64%	2.43%	2.65%	4.41%
EPS (Basic)	-12.80	-2.80	-0.80	-2.30	-0.10
EPS (Diluted)	-12.80	-2.80	-0.80	-2.30	-0.10
Free Cash Flow	5.47	-1.2	12.24	-0.44	0.07
Free Cash Flow Growth	-	-	-	-	-99.18%
Free Cash Flow Per Share	1.23	-0.28	2.89	-0.11	0.02
Gross Margin	57.67%	58.18%	58.86%	53.66%	56.90%
Operating Margin	-56.13%	-6.60%	1.69%	-6.12%	1.74%
Profit Margin	-75.69%	-18.97%	-7.01%	-10.38%	-2.10%
FCF Margin	6.32%	-1.28%	10.90%	-0.39%	0.06%
EBITDA	-42.64	0.95	8.89	0.64	9.69
EBITDA Margin	-49.26%	1.00%	7.92%	0.57%	8.15%
EBIT	-48.58	-6.21	1.89	-6.93	2.07
EBIT Margin	-56.13%	-6.60%	1.69%	-6.12%	1.74%
Effective Tax Rate	1.04%	-4.32%	-12.26%	-2.95%	-6.31%

Updated Mar 12, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q